Galapagos NV (GLPG) Given Daily Coverage Optimism Score of 0.24
Headlines about Galapagos NV (NASDAQ:GLPG) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Galapagos NV earned a daily sentiment score of 0.24 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 44.8853552925605 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Analysts Offer Insights on Healthcare Companies: Galapagos NV (NASDAQ: GLPG) and Aurinia Pharmaceuticals … – Analyst Ratings (analystratings.com)
- Healthcare Stock in Buy Zone: Galapagos NV (GLPG) – Street Observer (press release) (streetobserver.com)
- Stifel Nicolaus Upgrades Rating On Galapagos NV – American Deposit (GLPG) – First News 24 (firstnewspaper24.com)
- Stifel Upgrades Galapagos NV (GLPG) to Buy – StreetInsider.com (streetinsider.com)
- Galapagos announces phase IIa results with GLPG1690 in IPF patients (centerwatch.com)
Several research firms recently commented on GLPG. Zacks Investment Research raised Galapagos NV from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a report on Friday, July 14th. Stifel Nicolaus raised Galapagos NV from a “hold” rating to a “buy” rating and increased their target price for the company from $83.00 to $101.00 in a report on Friday. TheStreet raised Galapagos NV from a “d+” rating to a “c” rating in a report on Wednesday, May 17th. BTIG Research reissued a “buy” rating and issued a $98.00 target price on shares of Galapagos NV in a report on Tuesday, June 20th. Finally, Nomura increased their target price on Galapagos NV from $108.00 to $124.00 and gave the company a “buy” rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $96.14.
Galapagos NV (NASDAQ GLPG) opened at 83.73 on Friday. Galapagos NV has a one year low of $52.50 and a one year high of $94.88.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.